Latest Conference Articles

Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria

The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Ruxolitinib Improves Outcomes in aGVHD Across Subgroups

Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.

Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL

The triplet regimen of ibrutinib, venetoclax, and obinutuzumab demonstrated encouraging response rates with an acceptable safety profile in treatment-naïve patients with high-risk chronic lymphocytic leukemia.

Imetelstat Provides Promising, Durable Transfusion Independence in Lower-Risk MDS

Imetelstat demonstrated meaningful and durable transfusion independence in patients with lower-risk myelodysplastic syndrome that are non-del(5q), dependent on red blood cell transfusion, and are relapsed/refractory to treatment with erythropoiesis-stimulating agents.

Omitting Radiation Does Not Reduce Survival for Patients with Early Unfavorable HL

Radiation therapy can be omitted in patients with newly diagnosed early-stage unfavorable Hodgkin lymphoma without sacrificing efficacy.

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma

Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC

The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC

The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC

The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.

Cabozantinib Plus Atezolizumab Shows Promise in mCRPC

The combination of cabozantinib and atezolizumab showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer.

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC

Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.​​

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma

The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment

Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC

In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.

Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC

Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC

Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

Cabozantinib/Atezolizumab Combo Shows Promise in Previously Treated Urothelial Carcinoma

The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated promising objective responses in patients with urothelial carcinoma who progressed after receiving platinum-containing chemotherapy.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL

Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment

Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.

Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC

Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.

CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma

An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.

Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC

The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer

Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.